Published • loading... • Updated
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
- Vector Science & Therapeutics Corp. filed its first quarterly financial statements following its public listing via a reverse takeover with OpenSesame Acquisition Corp. on April 23, 2026.
- The company will hold its first quarterly investor Q&A on July 28, 2026, at 12:00 PM Eastern via Microsoft Teams.
- Vector expects to begin generating peptide manufacturing revenue in August 2026, aiming to scale production capacity to about 800,000 vials monthly by early fall with gross margins of 60% to 80%.
- VectorMist, a perioperative pain management technology for laparoscopic surgery, is planned for FDA 510 clearance submission and could generate revenue before the end of 2026 if approval is favorable.
Insights by Ground AI
31 Articles
31 Articles
Mason City Globe Gazette+30 Reposted by 30 other sources
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
Peptide manufacturing vertical on track to begin generating revenue in August 2026; VectorMist™ 510(k) submission advancing toward FDA filing
Coverage Details
Total News Sources31
Leaning Left4Leaning Right3Center20Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
15%
C 74%
11%
Factuality
To view factuality data please Upgrade to Premium
